BMS, Gilead and Sanofi lead Q3 2024 market cap growth

Nov 11, 2024 · The aggregate market capitalisation of the 20 largest drugmakers grew by 2% overall to reach $4.3tn. Among these, Bristol Myers Squibb, Gilead Sciences and Sanofi stood …

CouponFollow Extension

2%
OFF

BMS, Gilead And Sanofi Lead Q3 2024 Market Cap Growth

1 week from now

Nov 11, 2024 · The aggregate market capitalisation of the 20 largest drugmakers grew by 2% overall to reach $4.3tn. Among these, Bristol Myers Squibb, Gilead Sciences and Sanofi stood …

emjreviews.com

2%
OFF

Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25

1 week from now

Nov 8, 2024 · The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers Squibb, Gilead Sciences, and Sanofi, despite …

benzinga.com

2%
OFF

Top 20 Global Biopharmaceutical Companies Witness 2% Growth In …

1 week from now

Oct 29, 2024 · Bristol-Myers Squibb witnessed the largest growth in market capitalization of 24.6% to $105 billion in Q3 2024, fueled by robust pipeline progress and the FDA approval of …

globaldata.com

7%
OFF

Q3 2024 Results - Sanofi

1 week from now

Oct 25, 2024 · Q3 2024 company sales €13,438m +15.7% at constant exchange rates +12.3% on a reported basis Q3 2024 business earnings per share €2.86 +17.6% at constant exchange …

sanofi.com

€13
OFF

Business Finance Pipeline Appendices - Sanofi

1 week from now

Dupixent continues strong growth, on track for ~€13bn in 2024 Investor Relations All growth and Dupixent goal at CER. 1. Represents growth in Q3 2024 from Q3 2023. 2. IQVIA data with …

sanofi.com

6%
OFF

Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25

1 week from now

Nov 8, 2024 · Bristol-Myers Squibb & Co BMY led the market with the largest increase in capitalization, which surged by 24.6% to $105 billion. This was largely driven by …

tradingview.com

$11
OFF

Bristol Myers Squibb Reports Third Quarter Financial Results For …

1 week from now

Oct 31, 2024 · THIRD QUARTER RESULTS All comparisons are made versus the same period in 2023 unless otherwise stated. Bristol Myers Squibb posted third quarter revenues of $11.9 …

biospace.com

7%
OFF

Gilead Sciences Announces Third Quarter 2024 Financial Results

1 week from now

Nov 6, 2024 · Product Sales Excluding Veklury Increased 7% Year-Over-Year to $6.8 billion Biktarvy Sales Increased 13% Year-Over-Year to $3.5 billion Oncology Sales Increased 6% …

gilead.com

66%
OFF

Gilead Sciences Tops Estimates In Q3 | The Motley Fool

1 week from now

Nov 7, 2024 · Market Cap. $113B. Today's Change (-0.66%) -$0.60 ... Q3 2024 Analysts Estimate Q3 2023 Change (YOY) ... expected to bolster Gilead's lead in HIV prevention. Continued …

fool.com

30%
OFF

Gilead Increases 2024 Outlook, Expects New Drug Filing By End Of …

1 week from now

Nov 7, 2024 · In addition, Gilead reported adjusted earnings per share of $2.02, beating Wall Street expectations by nearly 30%. The stock is up nearly 6% Thursday, trading at more than …

yahoo.com

$74
OFF

After Celgene Deal, BMS Shoots Up Pharma Market Cap Rankings

1 week from now

Jan 9, 2025 · Bristol-Myers Squibb $74 billion takeover of Celgene saw it shoot up the list of top 20 pharma companies by market cap into the top 10, ... Gilead Sciences and Eli Lilly top of the …

pharmaphorum.com

FAQs about BMS, Gilead and Sanofi lead Q3 2024 market cap growth Coupon?

How did Bristol-Myers Squibb perform in Q3 2024?

Bristol-Myers Squibb witnessed the largest growth in market capitalization of 24.6% to $105 billion in Q3 2024, fueled by robust pipeline progress and the FDA approval of its antipsychotic drug Cobenfy for the treatment of schizophrenia in September 2024. ...

How did Gilead Sciences achieve its market capitalization growth?

Gilead Sciences achieved a market capitalization growth of 22.1%, owing to the FDA accelerated approval of its PPARD oral agonist Livdelzi for the treatment of primary biliary cholangitis, as well the approval of its antibody-drug conjugate (ADC) Trodelvy in Japan for the treatment of HR-/HER2- breast cancer. ...

Why did Sanofi increase its market capitalization in Q2 2024?

Sanofi reported a 19.2% increase in market capitalization due to the strong performance of its blockbuster drug Dupixent in Q2 2024 for the treatment of atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis and prurigo nodularis. ...

How did Gilead Sciences perform in third-quarter results?

Gilead Sciences posted robust revenue and EPS growth, exceeding expectations, and management raised full-year guidance. Virology and oncology treatments specialist Gilead Sciences (GILD 0.48%) reported third-quarter results on Wednesday, Nov. 6, that topped analysts' consensus estimates on top- and bottom lines. ...

Why did Gilead's non-GAAP EPs drop?

Despite these advances, Gilead reported lower earnings as non-GAAP EPS dropped to $2.02 compared to last year's $2.29. This decline stemmed largely from a $1.75 billion impairment of assets from its Immunomedics subsidiary. ...

How did Bristol Myers Squibb perform in third quarter?

Bristol Myers Squibb posted third quarter revenues of $11.9 billion, an increase of 8%, or 10% when adjusted for foreign exchange impacts, primarily driven by the Growth Portfolio and Eliquis , partially offset by generic erosion of Sprycel due to the loss of exclusivity. ...